- Anticipated business performance from government-funded organizations and private companies’ collaboration
- Advancing technological collaboration and joint marketing with cutting-edge equipment
[by Ji, Yong Jun] HLB bioStep announced on April 28 that it had entered into a ‘Memorandum of Understanding (MOU) for collaboration in non-clinical trials and R&D’ with the Korea Institute of Toxicology (KIT) at KIT’s headquarters.
Accordingly, the two parties will engage in various collaborative activities, including cooperation in primate 카지노 바카라, technical and information exchange, support for the development and commercialization of 카지노 바카라 and analysis methods, joint use of research facilities and equipment, and collaboration in non-clinical 카지노 바카라 education, among other initiatives.
The core focus of the agreement is the establishment of a joint research framework for primate 카지노 바카라. In line with this, both parties intend to actively collaborate in the field of primate microbiological 카지노 바카라 to enhance test quality and strengthen research reliability. Notably, they will conduct mutual technical cooperation in the analysis of biological samples and test materials, as well as in conducting advanced, image-based high-difficulty 카지노 바카라 using HLB bioStep’s cutting-edge equipment.
The two parties will also promote joint marketing initiatives and collaborate on packaged test orders. Leveraging their respective areas of expertise, they aim to flexibly address the diverse 카지노 바카라 needs of client institutions and contribute to strengthening the non-clinical research capabilities of Korean companies.
This agreement is anticipated to serve as a model case of public-private collaboration, as it brings together a government-funded research institute and a leading private company. In particular, it is expected to further strengthen the domestic non-clinical trial infrastructure by leveraging the expertise of both parties in securing and jointly utilizing primate 카지노 바카라 resources.
This agreement also aligns with the 카지노 바카라 Group’s efforts to strengthen its non-clinical research and development (R&D) strategy. In March, Baek Seong-jin, who previously assumed leadership of 카지노 바카라 bioCode, was newly appointed as CEO of 카지노 바카라 bioStep, and is currently spearheading the integration and synergy of the group’s non-clinical R&D initiatives.
“We have been steadily preparing to expand into the primate 카지노 바카라 field, and we anticipate that this collaboration will serve as a practical foundation for implementation and a catalyst for significant growth,” stated Baek Seong-jin, CEO of HLB bioStep. “We will actively cooperate to promote the mutual development of both parties.”
“We hope that this agreement will serve as a starting point for ongoing cooperation and technology sharing between both parties across a range of future research areas, including disease models, primate 카지노 바카라, messenger ribonucleic acid (mRNA), and organoids,” said Heo Jeong-doo, Director of KIT.